Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
Safety of Nintedanib in Real World in China
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05676112
Efficacy and Safety of Pirfenidone in CTD-ILD
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 120
- Registration Number
- NCT05505409
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05383131
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- PureTech
- Target Recruit Count
- 240
- Registration Number
- NCT05321420
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Science 37, Los Angeles, California, United States
Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 40
- Registration Number
- NCT05133453
Pirfenidone to Prevent Fibrosis in Ards.
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Università Vita-Salute San Raffaele
- Target Recruit Count
- 130
- Registration Number
- NCT05075161
- Locations
- 🇮🇹
A.O.R San Carlo, Potenza, Italy
🇮🇹IRCCS San Raffaele Scientific Institute, Milan, MI, Italy
Phase ll Study of HEC585 in Patients With IPF
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT05060822
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 58
- Registration Number
- NCT04971746
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Immunosuppressant Combined With Pirfenidone in CTD-ILD
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 200
- Registration Number
- NCT04928586
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 48
- Registration Number
- NCT04888715
- Locations
- 🇰🇷
Cha Unitersity Bundang Medical Center, Seongnam-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.